International AIDS Society
International AIDS Society

Industry Liaison Forum

The IAS-ILF is a mechanism to inform and support collaboration and partnership between industry, the IAS and other stakeholders. It performs this broad task by providing opportunities for industry to understand the IAS’s values, interests and priorities, and vice versa, seeking common ground to enhance the impact of the global response to HIV and related co morbidities.

The IAS-ILF aims to promote constructive interactions among all stakeholders, including industry, and convene experts from industry and non-industry organizations to discuss topics relevant to IAS Member Priorities. The IAS-ILF is designed to take advantage of the IAS’s key strengths: its well-respected convening power; its acknowledged independence towards industry and other key partners and stakeholders; and its diverse working groups composed of some of the world’s top thought leaders and scientific experts in a wide array of fields.

What's New

IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV
Removing barriers and seizing opportunities in paediatric HIV

Following the success of the IAS-ILF Industry Roundtable on Paediatric Antiretrovirals, held in Geneva, Switzerland, in November 2013, the IAS-ILF and the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) teamed up to organize a follow-up roundtable on paediatric HIV. This closed meeting was held in conjunction with AIDS 2014 (20-25 July 2014, Melbourne, Australia). It was aimed at bringing cohorts (through the CIPHER Cohort Collaboration) and industry together for an informal discussion and knowledge sharing between stakeholders, hoping to extend collaboration between cohort investigators and industry. Normative and regulatory agencies were also represented. The IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV was co-chaired by Lynne Mofenson (US National Institutes of Health, USA) and Shaffiq Essajee (Clinton Health Access Initiative, USA). This thematic roundtable highlighted the common goal shared by stakeholders: contributing to the development and distribution of better antiretroviral regimens to more infants, children and adolescents. Challenges and opportunities were highlighted during the discussion, as well as potential avenues for follow up through the CIPHER Cohort Collaboration.

The meeting agenda, report and presentations are available for download here.

IAS-ILF Corporate Partners


A list of previous sponsoring industry partners is available here.


  Facebook Twitter LinkedIn

20 January 2015
UN chief appoints new Special Envoy in move to end Tuberculosis

9 January 2015
FDA approves Roche's blood screening assay for simultaneous detection and identification of three major viral targets

7 January 2015
Manuel Gonçalves, Vice President and Head of External Affairs and Communication at ViiV Healthcare, becomes the IAS-ILF Industry Co-Chair, in replacement to Scott Purdon.

19 December 2014
AbbVie receives U.S. FDA approval of VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) for the treatment of chronic genotype 1 hepatitis C

15 December 2014
CLIA-waived HIV test enables earlier detection

12 December 2014
The IAS announces Amsterdam as site of the International AIDS Conference in July 2018

11 December 2014
As part of its continued commitment to ending paediatric HIV globally, the IAS announces a new collaboration with Janssen

3 December 2014
Sysmex Corporation joins the IAS-ILF Corporate Partnership Programme as an IAS-ILF Bronze Partner

2 December 2014
Zachary Who? Ken Mayer Boldly Goes Beyond Hype in the Age of PrEP

1 December 2014
World AIDS Day JIAS editorial: HIV and Ebola: similarities and differences

1 December 2014
The Medicines Patent Pool (MPP) signs licensing agreement with AbbVie for HIV paediatric formulations of lopinavir and ritonavir

1 December 2014
Global Pediatric Antiretroviral Commitment-to-Action to accelerate innovation and save children's lives

1 December 2014
The U.S. President's Emergency Plan for AIDS Relief, the Bill & Melinda Gates Foundation, and the Nike Foundation partner on $210 million initiative to reduce new HIV infections in adolescent girls and young women

18 November 2014
European Commission grants marketing authorization for Gilead’s Harvoni (Ledipasvir/Sofosbuvir)

15 November 2014
Call for public consultation: WHO Statement on Public Disclosure of Clinical Trial Results

9 November 2014
Gilead seeks approval for new HIV pill

7 November 2014
J&J wins U.S. approval for hepatitis C combo with Gilead

7 November 2014
Cavidi to support Partners in Health viral load program in Haiti

7 November 2014
Chembio earns CLIA waiver for HIV 1/2 assay, opening door to expansion

6 November 2014
Second European PrEP study closes placebo arm early due to high effectiveness

Articles from previous years are available here